Navigating Treatment Challenges for Rare Cancers: The Story of Mason Henderson

Date: September 21, 2026
Time: 5:00 AM EDT
Source: KFF Health News

Introduction:

Mason Henderson, a 21-year-old from southeastern Texas, faced relentless challenges after chemotherapy failed to combat his rare brain tumor, which had spread to his spinal fluid. In search of solutions, he traveled to New York City for a clinical trial, only to find the treatment unsuccessful. Henderson’s rare cancer type only received a name from the World Health Organization in 2021.

The Struggle for Treatment Options:

With standard care unavailable for such rare conditions, Henderson’s doctors sought alternatives based on detailed genetic analysis of his tumor. They decided on Lynparza, a drug from Merck and AstraZeneca. Despite their efforts, insurance refused coverage due to the absence of guidelines for Henderson’s specific cancer type. “They have no guidelines for his cancer,” his mother, Tabitha Lowe, expressed in an interview. “They’re discriminating against him because his cancer is so rare.”

The Prevalence of Rare Cancers:

Every year, tens of thousands in the U.S. are diagnosed with rare cancers, comprising about a quarter of all cancer cases.

Insurers usually rely on FDA labels and expert recommendations for reimbursement decisions. Rare cancers often lack targeted FDA-approved treatments, even though molecular testing can offer promising indications.

The Reality of Insurance Coverage:

Insurance coverage often lags behind genetic testing insights and scientific evidence, as pointed out by Olivier Elemento of Weill Cornell Medicine. Henderson’s neuro-oncologists tried Lynparza combined with chemotherapy based on biological rationale, though substantial evidence was limited. Despite positive responses in similar cases, insurance declined coverage, leaving the family with a potential $8,700 monthly cost.

Personal Impact:

Before his diagnosis, Henderson was an active and compassionate young man, aiming to become a police officer. The journey began when his brother discovered him post-seizure, leading to an MRI and subsequent diagnosis of diffuse hemispheric glioma (H3 G34-mutant) with a large tumor. Surgery and subsequent radiation and chemotherapy were sought, but the cancer persisted, spreading to the spinal cord.

The Search for an Effective Treatment:

Henderson underwent intense craniospinal irradiation as part of a clinical trial, yet the cancer remained. Providers remained hopeful about Lynparza’s potential, awaiting insurance or pharmaceutical company support. Despite the rarity and location of such tumors, increasing research aims to target specific mutations with tissue agnostic drugs.

Community and Family Efforts:

Faced with insurance denials, Lowe turned to social media for community support, eventually receiving Lynparza from AstraZeneca’s patient assistance program—six weeks after initial prescription. This came as Henderson’s health rapidly declined, and he passed away on May 4, leaving a void and prompting his family to establish a scholarship in his honor.

Continuing the Fight:

Reflecting on the experience, Lowe voiced the frustration of battling healthcare systems while trying to be there for her son, underscoring the urgency in handling paperwork when cancer doesn’t wait. The family’s initiative raised substantial funds through community events and donations, showing the power of collective support for rare cancer patients.